Nicox reported H122 results with operating cash burn rates mildly above our assumptions, while maintaining its guidance that its funds on hand should be sufficient to maintain operations into Q423, based on the development of NCX-470 alone. The company has pushed back its expected timeline for the release of primary efficacy data from the Denali NCX-470 Phase III study to after 2024 (from ‘after 2023’). Nicox has also decided to partner NCX-4251, its dry eye disease (DED) product candidate, for ....
22 Sep 2022
Nicox - Revising NCX-470 timelines given Denali delay
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Nicox - Revising NCX-470 timelines given Denali delay
Nicox reported H122 results with operating cash burn rates mildly above our assumptions, while maintaining its guidance that its funds on hand should be sufficient to maintain operations into Q423, based on the development of NCX-470 alone. The company has pushed back its expected timeline for the release of primary efficacy data from the Denali NCX-470 Phase III study to after 2024 (from ‘after 2023’). Nicox has also decided to partner NCX-4251, its dry eye disease (DED) product candidate, for ....